Besides identifying known kinase expression patterns and therapeutic targets in RCC subtypes such as FLT1 (ccRCC), KIT (chRCC and RO), and MET (pRCC type 1), we have identified several additional subtype-enriched kinases, with some among them being evaluated for their therapeutic utility in preclinical and clinical settings. Here, FLT1 is linked to nonpapillary renal cell carcinoma.